Background: Protease-activated receptor 2 (PAR-2) and IL-13 receptor α1 (IL-13Rα1) play major roles in type 2 inflammation. However, most of the literature was limited to allergic asthma.
Objective: This study examined how these receptors contribute to upper respiratory tract inflammation and explored potential therapeutic targets in patients with eosinophilic chronic rhinosinusitis (eCRS).
Methods: Using protein interaction analysis, animal experiments, and human tissue samples, we assessed the effects of exposure to house dust mite (HDM) allergen on PAR-2 and IL-13Rα1 activation and inflammatory markers, as well as the impact of the PAR-2 antagonist GB88. A fluorescent multiplex staining kit was used along with specific antibodies to label and detect proteins in the immunofluorescence tissue samples.
Results: Close relationship between PAR-2 (F2RL1), SPI-1, IL-13Rα1, and RNASE2 (EDN) was noted in protein interaction analysis. HDM exposure significantly activated PAR-2 and IL-13Rα1 in nasal epithelial cells, leading to Th2 cytokine release (IL-25, IL-33 & TSLP) and elevation of eosinophil proteins (ECP and EDN) that intensify upper respiratory tract inflammation. The PAR-2 antagonist GB88 reduced HDM allergen-induced PAR-2 and IL-13Rα1 expression, STAT-6 phosphorylation, and eosinophil infiltration, and decreased inflammatory markers. PAR2/SPI-1/ IL-13Rα1 was validated in IHC and IF analysis of human chronic rhinosinusitis specimens.
Conclusion: The PAR-2/IL-13Rα1 pathway is a promising target for treating upper respiratory tract inflammation. PAR-2 inhibitors could reduce inflammation and improve the outcomes of upper respiratory tract diseases, like eCRS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anai.2025.02.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protease-activated receptor 2 and IL-13Rα1 activation is linked to eosinophilic chronic rhinosinusitis.
Ann Allergy Asthma Immunol
March 2025
Department of Otolaryngology, Head and Neck Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; School of Medicine, National Defense Medical Center, Taipei, Taiwan; Department of Otolaryngology, Head and Neck Surgery, Tri-Service General Hospital, Taipei, Taiwan; Institute of Hospital and Health Care Administration, National Yang Ming Chiao Tung University, Taipei, Taiwan; School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan; Department of Early Childhood Care and Education, Cheng Shiu University. Electronic address:
Background: Protease-activated receptor 2 (PAR-2) and IL-13 receptor α1 (IL-13Rα1) play major roles in type 2 inflammation. However, most of the literature was limited to allergic asthma.
Objective: This study examined how these receptors contribute to upper respiratory tract inflammation and explored potential therapeutic targets in patients with eosinophilic chronic rhinosinusitis (eCRS).
Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome.
Epilepsia
March 2025
University of California San Francisco Weill Institute for Neurosciences, Benioff Children's Hospital, San Francisco, California, USA.
Objective: We analyzed the long-term safety and effectiveness of fenfluramine (FFA) in patients with Dravet syndrome (DS) in an open-label extension (OLE) study after participating in randomized controlled trials (RCTs) or commencing FFA de novo as adults.
Methods: Patients with DS who participated in one of three RCTs or were 19 to 35 years of age and started FFA de novo were included. Key endpoints were: incidence of treatment-emergent adverse events (TEAEs) in the safety population, and median percentage change in monthly convulsive seizure frequency (MCSF) from the RCT baseline to end of study (EOS) in the modified intent-to-treat (mITT) population.
Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial.
J Dermatol
March 2025
Pfizer Japan Inc, Tokyo, Japan.
This subgroup analysis of the ALLEGRO phase 2b/3 study (NCT3732807) assessed the efficacy and safety of multiple doses of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in Asian patients with alopecia areata (AA). Patients aged ≥12 years with AA and ≥50% scalp hair loss received once-daily ritlecitinib 50 or 30 mg (with or without 4-week 200-mg loading dose ["200/50" or "200/30"]) or 10 mg or placebo for 24 weeks, followed by a 24-week extension, in which patients initially assigned to placebo switched to 200/50 or 50 mg. In this subgroup analysis, Asian patients with response based on achieving a Severity of Alopecia Tool (SALT) score ≤20, SALT ≤10, ≥2-grade improvement or normal score on the eyebrow assessment (EBA) scale, and ≥2-grade improvement or normal score on the eyelash assessment (ELA) scale were evaluated through week 48.
View Article and Find Full Text PDFNavigating Diagnostic Uncertainty: A Neck Swelling in an Elderly Patient Prompting Reflection on Over-investigation.
Indian J Otolaryngol Head Neck Surg
January 2025
Department of Otorhinolaryngology, St Johns Medical College, Bangalore, Karnataka 560034 India.
A brief communication report highlighting a 69-year-old male with a history of chronic conditions who presented with a persistent neck swelling following an upper respiratory tract infection. Despite multiple benign findings from various diagnostic procedures, the patient's anxiety about a potential malignancy led to repeated investigations, culminating in a left-sided neck dissection. The case underscores the challenges of managing patient-driven demands for certainty in an era of defensive medicine, where physicians may feel compelled to order excessive tests.
View Article and Find Full Text PDFEmergence of a novel reassortant H3N3 avian influenza virus with enhanced pathogenicity and transmissibility in chickens in China.
Vet Res
March 2025
Fujian Province Joint Laboratory of Animal Pathogen Prevention and Control of the "Belt and Road", College of Animal Sciences, Fujian Agriculture and Forestry University, Fuzhou, 350002, Fujian, China.
H3N3 avian influenza viruses (AIVs) are less prevalent in poultry than H3N8 viruses. However, although relatively rare, reassortant H3N3 viruses have been known to appear in both domestic poultry and wild birds. In this study, we isolated the H3N3 virus in chickens sourced from a live poultry market in China.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!